

SWIXX SELECTED AS GILEAD'S BALTIC PARTNER

SWIXX ANNOUNCEMENT NO. 44

December 16th, 2021

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland announced today the signature of a contract with Gilead Sciences. Under the agreement, Swixx will be exclusively responsible to commercialize and distribute Gilead's key products in HIV and Hepatitis C (HCV) in the three Baltic countries of Estonia, Latvia and Lithuania effective January 1st, 2022.

"This contract marks an important evolution for our Baltic operations," commented Swixx's Regional GM for the Baltics, Dr. Saulius Zemaitis. "Gilead has an exciting pipeline of innovative specialty treatments which are highly synergistic with Swixx's existing portfolio. We look forward to dedicating our growing Baltic team – which will number more than seventy professionals as of 2022 first quarter – to the challenge of widening and securing access for Baltic HIV and HCV patients to Gilead's medicines. It's an honour and privilege to work with these breakthrough medicines, which represent new hope for our patients," continued Zemaitis. "I would like to express our team's sincere thanks to Gilead for affording Swixx this opportunity."

Dr. Laur Saar, Swixx's Head of Medical & Regulatory Affairs based in Estonia also welcomed the new contract. "It is our hope to work intensively with the Baltic medical community to bring these Gilead therapies into broader use," Saar commented. "In addition to launching the company's breakthrough HIV and HCV medicines in the Baltics, we will continue to make available the other medicines within Gilead's portfolio."

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With over 900 employees and sales likely to exceed 600M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and CHC companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321